The Neurodevelopmental Pathogenesis of Tuberous Sclerosis Complex (TSC)

被引:36
|
作者
Feliciano, David M. [1 ]
机构
[1] Clemson Univ, Dept Biol Sci, Clemson, SC 29634 USA
来源
FRONTIERS IN NEUROANATOMY | 2020年 / 14卷
基金
美国国家卫生研究院;
关键词
TSC1; TSC2; mTOR; Tuber; SEGA; subependymal giant cell astrocytoma; FOCAL CORTICAL DYSPLASIA; GIANT-CELL ASTROCYTOMAS; AUTISTIC-LIKE BEHAVIOR; INDUCED RENAL TUMORS; EKER RAT MODEL; MOUSE MODEL; SOMATIC MUTATIONS; EPILEPSY SURGERY; MAMMALIAN TARGET; MTOR PATHWAY;
D O I
10.3389/fnana.2020.00039
中图分类号
R602 [外科病理学、解剖学]; R32 [人体形态学];
学科分类号
100101 ;
摘要
Tuberous sclerosis complex (TSC) is a model disorder for understanding brain development because the genes that cause TSC are known, many downstream molecular pathways have been identified, and the resulting perturbations of cellular events are established. TSC, therefore, provides an intellectual framework to understand the molecular and biochemical pathways that orchestrate normal brain development. The TSC1 and TSC2 genes encode Hamartin and Tuberin which form a GTPase activating protein (GAP) complex. Inactivating mutations in TSC genes (TSC1/TSC2) cause sustained Ras homologue enriched in brain (RHEB) activation of the mammalian isoform of the target of rapamycin complex 1 (mTORC1). TOR is a protein kinase that regulates cell size in many organisms throughout nature. mTORC1 inhibits catabolic processes including autophagy and activates anabolic processes including mRNA translation. mTORC1 regulation is achieved through two main upstream mechanisms. The first mechanism is regulation by growth factor signaling. The second mechanism is regulation by amino acids. Gene mutations that cause too much or too little mTORC1 activity lead to a spectrum of neuroanatomical changes ranging from altered brain size (micro and macrocephaly) to cortical malformations to Type I neoplasias. Because somatic mutations often underlie these changes, the timing, and location of mutation results in focal brain malformations. These mutations, therefore, provide gain-of-function and loss-of-function changes that are a powerful tool to assess the events that have gone awry during development and to determine their functional physiological consequences. Knowledge about the TSC-mTORC1 pathway has allowed scientists to predict which upstream and downstream mutations should cause commensurate neuroanatomical changes. Indeed, many of these predictions have now been clinically validated. A description of clinical imaging and histochemical findings is provided in relation to laboratory models of TSC that will allow the reader to appreciate how human pathology can provide an understanding of the fundamental mechanisms of development.
引用
收藏
页数:18
相关论文
共 50 条
  • [21] The tuberous sclerosis complex (TSC) pathway and mechanism of size control
    Potter, CJ
    Pedraza, LG
    Huang, H
    Xu, T
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2003, 31 : 584 - 586
  • [22] Ocular Phenotype and Complications in Patients with Tuberous Sclerosis Complex (TSC)
    Zweipfenning, Florian
    Toelle, Sandra P.
    Gerth-Kahlert, Christina
    KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 2019, 236 (04) : 462 - 468
  • [23] Preventive Epilepsy Therapy in Patients with Tuberous Sclerosis Complex (TSC)
    Grigorieva, A. V.
    Dorofeeva, M. Y.
    Gorchkhanova, Z. K.
    Belousova, E. D. G. A. V.
    Dorofeeva, M. Y.
    Gorchkhanova, Z. K.
    Belousova, E. D.
    EPILEPSIA, 2018, 59 : S291 - S291
  • [24] Animal Models of Lymphangioleiomyomatosis (LAM) and Tuberous Sclerosis Complex (TSC)
    Kwiatkowski, David J.
    LYMPHATIC RESEARCH AND BIOLOGY, 2010, 8 (01) : 51 - 57
  • [25] Treatment of renal angiomyolipoma in tuberous sclerosis complex (TSC) patients
    Brakemeier, S.
    Bachmann, F.
    Budde, K.
    PEDIATRIC NEPHROLOGY, 2017, 32 (07) : 1137 - 1144
  • [26] RESULTS OF THE COLLABORATIVE STUDY ON TUBEROUS SCLEROSIS COMPLEX (TSC) IN ITALY
    BALESTRI, P
    BARTALINI, G
    BIANCHI, E
    BOSIO, M
    BUTI, D
    CALISTRI, L
    CALVIERI, S
    CASADEI, G
    BERNARDINA, BD
    DECOSMO, L
    DENARDO, V
    DELGIUDICE, E
    DINELLI, P
    DORDI, B
    FAGGIOLI, R
    FARNETANI, MA
    FOIS, A
    FURCAS, F
    GABRIELE, G
    GALLI, V
    GELLI, GP
    GIORGI, PL
    LABUONORA, GI
    LANZA, G
    LECCHINI, P
    LOI, M
    LUNGAROTTI, MS
    LUXARDO, P
    MACCHERINI, M
    MORETTI, M
    NURCHI, AM
    PALLOTTA, R
    PALMIERI, C
    PECENCO, G
    PIATTELLA, L
    PISTONE, FM
    ROSATI, C
    ROSSI, LN
    RUSSO, U
    SALANI, M
    TADDEUCCI, G
    TINE, A
    VERDURA, G
    VIVARELLI, R
    RIVISTA ITALIANA DI PEDIATRIA-ITALIAN JOURNAL OF PEDIATRICS, 1994, 20 (06): : 654 - 670
  • [27] Molecularly targeted intervention for cognition in Tuberous Sclerosis Complex (TSC)
    de Vries, P. J.
    McCartney, D. L.
    JOURNAL OF INTELLECTUAL DISABILITY RESEARCH, 2008, 52 : 656 - 656
  • [28] Treatment of renal angiomyolipoma in tuberous sclerosis complex (TSC) patients
    S. Brakemeier
    F. Bachmann
    K. Budde
    Pediatric Nephrology, 2017, 32 : 1137 - 1144
  • [29] Tuberous sclerosis complex (TSC) gene involvement in sporadic tumours
    Knowles, MA
    Hornigold, N
    Pitt, E
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2003, 31 : 597 - 602
  • [30] Phenotypic Variability in Tuberous Sclerosis Complex (TSC): Genetic Modifiers
    Narayanan, V
    Sekar, S.
    MacKiegan, J.
    Liang, W.
    Rangasamy, S.
    ANNALS OF NEUROLOGY, 2016, 80 : S310 - S311